| Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch, J Andréll, ... Med 2 (3), 281-295. e4, 2021 | 205 | 2021 |
| Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant F Zuo, H Abolhassani, L Du, A Piralla, F Bertoglio, L de Campos-Mata, ... Nature communications 13 (1), 2670, 2022 | 132 | 2022 |
| A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations F Bertoglio, V Fühner, M Ruschig, PA Heine, L Abassi, T Klünemann, ... Cell reports 36 (4), 109433, 2021 | 88* | 2021 |
| Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant M Schubert, F Bertoglio, S Steinke, PA Heine, MA Ynga-Durand, H Maass, ... BMC medicine 20 (1), 102, 2022 | 84 | 2022 |
| SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface F Bertoglio, D Meier, N Langreder, S Steinke, U Rand, L Simonelli, ... Nature communications 12 (1), 1577, 2021 | 82 | 2021 |
| Human antibodies neutralizing diphtheria toxin in vitro and in vivo EV Wenzel, M Bosnak, R Tierney, M Schubert, J Brown, S Dübel, ... Scientific reports 10 (1), 571, 2020 | 59 | 2020 |
| Immunity to SARS-CoV-2 up to 15 months after infection H Marcotte, A Piralla, F Zuo, L Du, I Cassaniti, H Wan, M Kumagai-Braesh, ... IScience 25 (2), 103743, 2022 | 54 | 2022 |
| Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy KDR Roth, EV Wenzel, M Ruschig, S Steinke, N Langreder, PA Heine, ... Frontiers in cellular and infection microbiology 11, 697876, 2021 | 53 | 2021 |
| Baculovirus-free insect cell expression system for high yield antibody and antigen production J Korn, D Schäckermann, T Kirmann, F Bertoglio, S Steinke, J Heisig, ... Scientific reports 10 (1), 21393, 2020 | 32 | 2020 |
| Genomic Analysis and Isolation of RNA Polymerase II Dependent Promoters from Spodoptera frugiperda M Bleckmann, MHY Fritz, S Bhuju, M Jarek, M Schürig, R Geffers, ... PLoS One 10 (8), e0132898, 2015 | 32 | 2015 |
| Identification of essential genetic baculoviral elements for recombinant protein expression by transactivation in Sf21 insect cells M Bleckmann, M Schürig, FF Chen, ZZ Yen, N Lindemann, S Meyer, ... PLoS One 11 (3), e0149424, 2016 | 29 | 2016 |
| Identifying parameters to improve the reproducibility of transient gene expression in High Five cells M Bleckmann, M Schürig, M Endres, A Samuels, D Gebauer, N Konisch, ... PLoS One 14 (6), e0217878, 2019 | 22 | 2019 |
| ChAdOx1‐S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination M Cokarić Brdovčak, J Materljan, M Šustić, S Ravlić, T Ružić, B Lisnić, ... European Journal of Immunology 52 (6), 936-945, 2022 | 19 | 2022 |
| Quantification of polyreactive immunoglobulin G facilitates diagnosis of autoimmune hepatitis B Engel, R Taubert, J Diestelhorst, KL Hupa-Breier, E Saunders, ... JOURNAL OF HEPATOLOGY 75, S423-S423, 2021 | 18* | 2021 |
| The long term vaccine‐induced anti‐SARS‐CoV‐2 immune response is impaired in quantity and quality under TNFα blockade UM Geisen, R Rose, F Neumann, M Ciripoi, L Vullriede, HM Reid, ... Journal of Medical Virology 94 (12), 5780-5789, 2022 | 16 | 2022 |
| Not Limited to E. coli: Versatile Expression Vectors for Mammalian Protein Expression K Karste, M Bleckmann, J van den Heuvel Heterologous Gene Expression in E. coli: Methods and Protocols, 313-324, 2017 | 12 | 2017 |
| Fast plasmid based protein expression analysis in insect cells using an automated SplitGFP screen M Bleckmann, S Schmelz, C Schinkowski, A Scrima, J van den Heuvel Biotechnology and Bioengineering 113 (9), 1975-1983, 2016 | 11 | 2016 |
| Novel colloidal associations of soyasaponins and lipid components (DPPC, cholesterol) as potential adjuvants for vaccines C de Groot, M Müsken, M Bleckmann, T Ebensen, CA Guzmán, ... Vaccine 37 (35), 4975-4986, 2019 | 9 | 2019 |
| Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat Commun. 2022; 13: 2670 F Zuo, H Abolhassani, L Du, A Piralla, F Bertoglio, L de Campos-Mata, ... DOI: https://doi. org/10.1038/s41467-022-30340-5. PMID: https://www. ncbi …, 0 | 9 | |
| SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study PK Brlić, M Pavletić, M Lerga, F Krstanović, MP Matešić, K Miklić, S Malić, ... Viruses 14 (9), 1966, 2022 | 8 | 2022 |
